Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. - Wikidata - awgldk - TriplyDB

Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome.

Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome.

http://www.wikidata.org/entity/Q46367698

about

Oxidative stress in the pathogenesis of atherothrombosis associated with anti-phospholipid syndrome and systemic lupus erythematosus: new therapeutic approaches Coronary artery disease in patients with systemic lupus erythematosus Nephritis and the risk of acute myocardial infarction in patients with systemic lupus erythematosus The relationship between race, cigarette smoking and carotid intimal medial thickness in systemic lupus erythematosus.Management of cardiovascular complications in systemic lupus erythematosus.Thyroid antibodies, autoimmunity and cognitive decline: is there a population-based link?Cardiovascular risk factors in the antiphospholipid syndrome Aortic Atherosclerosis in Systemic Lupus Erythematosus Paraoxonase-3 is depleted from the high-density lipoproteins of autoimmune disease patients with subclinical atherosclerosis.Nonorgan specific autoantibodies and heart damage.Atherogenesis in rheumatology.Heart involvement in systemic lupus erythematosus, anti-phospholipid syndrome and neonatal lupus.Premature aortic atherosclerosis in systemic lupus erythematosus: a controlled transesophageal echocardiographic study Advances in lupus and Sjögren's syndrome: a tribute to Josep Font.Genomics and proteomics: a new approach for assessing thrombotic risk in autoimmune diseases.Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort European Forum on Antiphospholipid Antibodies: research in progress.Cutting-edge issues in coronary disease and the primary antiphospholipid syndrome.Anti-β2-glycoprotein I antibodies.Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus.Tomography and blood vessels in Hughes syndrome.Markers of cardiovascular risk in patients with antiphospholipid syndrome: a meta-analysis of literature studies.Biomarkers for cardiovascular risk assessment in autoimmune diseases.Reduced carotid intima-media thickness in systemic lupus erythematosus patients treated with cyclosporine A.Endothelial progenitor dysfunction associates with a type I interferon signature in primary antiphospholipid syndrome.Dyslipidemia and its relationship with antiphospholipid antibodies in APS patients in North Kerala.Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus.High-density lipoprotein inversely relates to its specific autoantibody favoring oxidation in thrombotic primary antiphospholipid syndrome.High-density lipoproteins are abnormal in young women with uncomplicated systemic lupus erythematosus.Carotid atherosclerotic alterations in systemic lupus erythematosus patients treated at a Brazilian university setting.Subclinical atherosclerosis in primary antiphospholipid syndrome.Abdominal pain in patient with antiphospholipid syndrome-the role of MDCT angiography on visceral blood vessels.Increased arterial stiffness correlated with disease activity in systemic lupus erythematosus.Atherosclerosis in primary antiphospholipid syndrome.

P2860

Q28075691-EE610C2F-6589-4FF1-A778-CE1DAA586562 Q28200286-CD641A89-F910-4E37-9861-0DAC5DFA5FE4 Q33389669-85928A1C-0748-45EE-8EAA-4F9A9DAC5D05 Q33584053-A73F503F-56AA-4855-A9F6-BE11B1F754F9 Q33730536-30CC8ECF-0790-4995-84A7-9AAED81EB09A Q33795238-7905E981-F587-496B-9B8C-EBB5F56394DE Q34003460-F6951512-2AF2-48F4-8E8A-463765FE8733 Q34938841-112C63EB-5F5D-434F-B315-261534229538 Q35615662-6591AC21-F8D8-47D3-9743-71B665ED0031 Q36283415-B7F20AD6-2A47-45AC-A07C-ED971B13C604 Q36458127-68620B8A-A7A3-43CA-9BD4-3086F8FFAFEC Q36596375-254539EB-CF45-4E10-A64E-DF1061260956 Q36598459-C0EFEBF9-A55F-4489-AC2D-37D0699F9255 Q36951011-B0A71E6A-9E5D-447E-A4D0-EE12344449C3 Q37283020-03C4F8B9-A07D-4340-85CA-B27B102D27A9 Q37406201-7C794296-308E-45B3-88BD-978B3D6F06E8 Q37578126-3A788242-78D1-4113-9620-3AF6EBABFFC0 Q37853050-534FC15F-BE07-4F1A-A2C5-FAA97543D6FA Q38108396-2845164C-E213-493B-8995-773CC77E8B26 Q38162490-3513967C-3DFF-43CC-B707-2093CD1185FB Q38179334-3085A775-5550-4959-B5F7-45E0C6E198C6 Q38259336-EF458F98-3BE9-434D-BD5F-F41897146F45 Q38293735-03F35D11-332E-469D-BBD2-6F813F5F2690 Q39310529-294AAB3A-372A-4358-A654-0335D2056DF4 Q39586997-B5E1AF04-2A0B-492D-A6FE-086A27F537A4 Q42325625-2829CDF0-DDDC-438B-8FF9-30F89A90D301 Q42647843-9B40E736-1B53-46B8-8818-0CAE29D55A6F Q43197413-86A7960E-E25A-439C-A1CE-C3490B47FE4B Q46318778-40014F8C-94DA-4C7F-92F5-ED13151B7EAD Q46771777-FFA4C85F-6F78-4CE8-AF26-3A73E4FF8640 Q46982844-DF7D5FB7-5A32-4444-87F5-4E14CDA270A2 Q48310219-0A7277D1-258B-403B-9A1C-318BFC899F81 Q51672774-E29FB025-F20E-44E7-AD3A-CE90CC856F91 Q52852275-F559BCEF-81C6-47FD-8252-D190FE62455D

P2860

Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome.

http://www.wikidata.org/entity/Q46367698

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Preclinical vascular disease i ...... ary antiphospholipid syndrome.

@en

Preclinical vascular disease i ...... ary antiphospholipid syndrome.

@nl

type

label

Preclinical vascular disease i ...... ary antiphospholipid syndrome.

@en

Preclinical vascular disease i ...... ary antiphospholipid syndrome.

@nl

prefLabel

Preclinical vascular disease i ...... ary antiphospholipid syndrome.

@en

Preclinical vascular disease i ...... ary antiphospholipid syndrome.

@nl

P1433

Q46367698-F0C8DD26-B600-426A-B411-C7B2EA032FF2

P1476

Q46367698-1E039741-6193-4B70-9832-40634163D53F

P2093

Q46367698-061D2ADF-C956-47FF-9335-7EA7B0A53A1B

Q46367698-0D32F72B-3DAB-4292-A25F-B3C3E017215B

Q46367698-667B4091-1183-483F-B2FA-6829E625A5F2

Q46367698-7597488A-645B-4301-9432-A25299DFD0FA

Q46367698-8D794926-D6E7-4C41-8829-312E7743596E

Q46367698-D49ACC67-ABB1-4E6D-8FA4-66FABFE8DCC3

P2860

Q46367698-10A465BD-6D06-41BE-AC12-C0C1050571AF

Q46367698-1B3E0BC0-2417-4DDA-B1D7-C9D64D206EE9

Q46367698-2357F7B0-26A8-46BD-840F-2583DA9AD5CB

Q46367698-398FD6D0-C83D-4D1F-964A-939CCFFF1E50

Q46367698-3B28AE78-3C0E-4FBF-B720-AA17F79A0C64

Q46367698-43D42EF5-2C09-432C-8386-88077409160C

Q46367698-497619A6-F688-487B-BDD1-FBD163D5E4D7

Q46367698-49AB8120-A814-463A-A9D2-24DDBEE742EF

Q46367698-52ECA9D0-8773-411A-B396-EFAE8938E647

Q46367698-5DFD5830-14DB-40EC-BA02-9C3455ED3C0B

P304

Q46367698-7C02B7AC-6E93-4000-B877-43DFB0BB6FC9

P31

Q46367698-C9CC34AC-B9C1-4942-8ED5-AE4EC793B605

P356

Q46367698-8F78EBCA-FEAF-4734-80C4-F14B08536C8C

P433

Q46367698-990E6FD6-07B9-422B-BF5C-4FA7B1B9A172

P478

Q46367698-389C6B17-C811-4ED6-A368-0990FDD479AC

P50

Q46367698-0CEE0928-A6BF-4658-84EF-97848D6F5379

Q46367698-712D47CA-FC5E-4A04-9010-68E80E320DA7

Q46367698-894ED4CA-C7E8-4410-AF57-37FEC217D656

Q46367698-9494E7A1-31E8-4934-A231-440639FBDA38

P577

Q46367698-325992C3-8F3B-43C1-B449-C3FEC6931028

P5875

Q46367698-E0A3BDB4-5E13-477A-9BE1-2DD25193ECD9

P698

Q46367698-9BC3A57D-FB5B-4571-B482-D0083A33A4B9

P356

P1433

P1476

Preclinical vascular disease i ...... ary antiphospholipid syndrome.

@en

P2093

Concepció Bru

http://www.w3.org/2001/XMLSchema#string

Daniel Zambón

http://www.w3.org/2001/XMLSchema#string

Dolors Tàssies

http://www.w3.org/2001/XMLSchema#string

M Angels García-Criado

http://www.w3.org/2001/XMLSchema#string

M Rosa Gilabert

http://www.w3.org/2001/XMLSchema#string

Sònia Jiménez

http://www.w3.org/2001/XMLSchema#string

P2860

Reduction of atherosclerosis in mice by inhibition of CD40 signalling

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients.

Lupus erythematosus in the 1980s: a survey of 570 patients.

Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death.

Anticardiolipin antibodies: isotype distribution and phospholipid specificity.

International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop.

Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus.

Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus

P304

756-761

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/RHEUMATOLOGY/KEH581

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

44

http://www.w3.org/2001/XMLSchema#string

P50

Joan Carles Reverter Calatayud

P577

2005-03-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7976406

http://www.w3.org/2001/XMLSchema#string

P698

15757967

http://www.w3.org/2001/XMLSchema#string